Irisin, a New Biomarker in Diagnosis of Atherosclerosis and Myocardial Infarction

Document Type : Original Article (s)

Authors

1 MSC Student, Department of Biochemistry, Falavarjan Branch, Islamic Azad University, Isfahan, Iran

2 Assistant Professor, Department of Biochemistry, Falavarjan Branch, Islamic Azad University, Isfahan, Iran

3 Associate Professor, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Measuring biomarkers has become of the most useful methods for diagnosis cardiovascular diseases (CVD), due to the simplicity and accessibility. Irisin, a newly discovered myokine, has been recently introduced as a potential biomarker for diagnosis of myocardial infarction (MI). Recent studies showed that irisin decreases significantly in patients with myocardial infarction. The present study aimed to explore the irisin concentration in men with atherosclerosis or myocardial infarction, compared to control group.Methods: This cross-sectional controlled trial study conducted on 75 Iranian men in three groups of myocardial infarction, angiography test-positive and control. Anthropometric parameters (height, weight, waist and hip circumference) were measured at the first step. Blood collection was done within 48 hours after chest pain initiation in patients with myocardial infarction (for determination of serum troponin, creatine kinase-MB (CK-MB), high-sensitivity C-reactive protein (hsCRP) and irisin concentration); and after a 10-12 hours fasting in angiography-positive and control groups (for determination of serum lipid profile, hsCRP and irisin concentration).Findings: Irisin concentration was significantly lower in myocardial infarction and in angiography-positive groups compared to the control group. There was not significant difference in irisin concentration between the myocardial infarction angiography-positive groups.Conclusion: Decreasing of irisin concentration in patient with myocardial infarction might be a protective response. There is a possibility that if irisin would not be decreased, there would be a bigger tissue damaging due to the energy depletion.

Keywords

References

  1. Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012; 481(7382): 463-8.
  2. Kelly DP. Medicine. Irisin, light my fire. Science 2012; 336(6077): 42-3.
  3. Villarroya F. Irisin, turning up the heat. Cell Metab 2012; 15(3): 277-8.
  4. Kuloglu T, Aydin S, Eren MN, Yilmaz M, Sahin I, Kalayci M, et al. Irisin: a potentially candidate marker for myocardial infarction. Peptides 2014; 55: 85-91.
  5. Aydin S, Aydin S, Kobat MA, Kalayci M, Eren MN, Yilmaz M, et al. Decreased saliva/serum irisin concentrations in the acute myocardial infarction promising for being a new candidate biomarker for diagnosis of this pathology. Peptides 2014; 56: 141-5.
  6. Panagiotou G, Mu L, Na B, Mukamal KJ, Mantzoros CS. Circulating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular risk. Metabolism 2014; 63(10): 1265-71.
  7. Ahmadi A, Soori H, Mehrabi Y, Etemad K, Samavat T, Khaledifar A. Incidence of acute myocardial infarction in Islamic Republic of Iran: a study using national registry data in 2012. East Mediterr Health J 2015; 21(1): 5-12.
  8. Baradaran A, Nasri H. Serum cholesterol as a marker of nutrition in end-stage renal failure patients on renal replacement therapy. International Journal of Pharmacology 2006; 2(2): 184-7.
  9. Ahmadi A, Soori H, Mehrabi Y, Etemad K, Khaledifar A. Epidemiological pattern of myocardial infarction and modelling risk factors relevant to in-hospital mortality: the first results from the Iranian Myocardial Infarction Registry. Kardiol Pol 2015; 73(6): 451-7.
  10. Nasri H, Baradaran A. Lipids in association with leptin in maintenance hemodialysis patients. J Med Sci 2006; 6(2): 173-9.
  11. Ahmadi A, Hasanzadeh J, Rajaeifard A. Metabolic control and care assessment in patients with type 2 diabetes In Chaharmahal and Bakhtiyari Province 2008. Iran J Endocrinol Metab 2009; 11(1): 33-9. [In Persian].
  12. Nasri H, Behradmanesh S, Ahmadi A, Rafieian-Kopaei M. Impact of oral vitamin D (cholecalciferol) replacement therapy on blood pressure in type 2 diabetes patients; a randomized, double-blind, placebo controlled clinical trial. J Nephropathol 2014; 3(1): 29-33.
  13. Beladi-Mousavi SS, Bashardoust B, Nasri H, Ahmadi A, Tolou-Ghamari Z, Hajian S, et al. The theme of the world diabetes day 2014; healthy living and diabetes; a nephrology view point. J Nephropharmacol 2014; 3(2): 43-5.
  14. Nasri H, Yazdani M. The relationship between serum LDL-cholesterol, HDL-cholesterol and systolic blood pressure in patients with type 2 diabetes. Kardiol Pol 2006; 64(12): 1364-8.
  15. Nasri H, Baradaran A. Association of serum lipoprotein(a) with ultrasonographically determined early atherosclerotic changes in the carotid and femoral arteries in kidney transplanted patients. Transplant Proc 2004; 36(9): 2683-6.
  16. Ahmadi A, Soori H, Sajjadi H, Nasri H, Mehrabi Y, Etemad K. Current status of the clinical epidemiology of myocardial infarction in men and women: a national cross-sectional study in iran. Int J Prev Med 2015; 6: 14.
  17. Nasri H. Serum C-reactive protein (CRP) in association with various nutritional parameters in maintenance hemodialysis patients. Bratisl Lek Listy 2005; 106(12): 390-5.
  18. Nasri H, Ahmadi A, Baradaran A, Momeni A, Nasri P, Mardani S, et al. Clinicopathological correlations in lupus nephritis; a single center experience. J Nephropathol 2014; 3(3): 115-20.
  19. Ghaderian SB, Beladi-Mousavi SS. The role of diabetes mellitus and hypertension in chronic kidney disease. J Renal Inj Prev 2014; 3(4): 109-10.
  20. Beladi-Mousavi SS, Bashardoust B, Nasri H, Ahmadi A, Tolou-Ghamari Z, Hajian Sh. Serum uric acid level and its association with cardio-metabolic risk factors in prediabetics. J Parathyr Dis 2014; 2(1): 51-2.
  21. Gouni-Berthold I, Berthold HK, Huh JY, Berman R, Spenrath N, Krone W, et al. Effects of lipid-lowering drugs on irisin in human subjects in vivo and in human skeletal muscle cells ex vivo. PLoS One 2013; 8(9): e72858.
Journal of Isfahan Medical School
Volume 33, Issue 350 - Serial Number 350
July and August 2015
Pages 1506-1516

Files

History

  • Receive Date: 24 June 2015
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics